Details

Autor(en) / Beteiligte

• Ohmoto, Akihiro
• Nakano, Kenji
• Fukuda, Naoki
• Wang, Xiaofei
• Urasaki, Tetsuya
• Hayashi, Naomi
• Suto, Hirotaka
• Udagawa, Shohei
• Oki, Ryosuke
• Sato, Yasuyoshi
• Yunokawa, Mayu
• Ono, Makiko
• Saito, Masanori
• Minami, Yusuke
• Hayakawa, Keiko
• Tanizawa, Taisuke
• Ae, Keisuke
• Matsumoto, Seiichi
• Tomomatsu, Junichi
• Takahashi, Shunji
• Benjamin, Robert S

Titel

Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study

Ist Teil von

• PloS one, 2023-03, Vol.18 (3), p.e0280508-e0280508

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve long-term disease control with this treatment. However, the reference information is insufficient. Herein, we retrospectively reviewed 51 sarcoma patients who received trabectedin. We analyzed the clinicopathological features, trabectedin dose, administration schedule, and clinical outcomes, including the overall response rate (ORR) and PFS. Among them, we assessed the detailed data of patients who achieved long-term disease control (PFS >1 year). The ORR in the 49 evaluable patients was 8%, and the median PFS in 51 patients was 7.5 months. Six patients (12%) achieved PFS of >1 year. Five of the six patients had metastatic lesions at trabectedin initiation. The pathological subtypes were myxoid liposarcoma (n = 2), leiomyosarcoma (n = 2), synovial sarcoma (n = 1), and Ewing sarcoma (n = 1). The final administration dose was the minimum dose (0.8 mg/m2) in two patients who continued the treatment over 20 cycles. The best radiological response was partial response (PR) in two myxoid liposarcoma patients and stable disease in four. The durations from trabectedin initiation to the first response in the two PR cases were 163 and 176 days, respectively. Our results support the validity of continuing trabectedin at a sustainable dose and interval in patients who can tolerate it. These results may be useful when considering the clinical application of trabectedin.